FDA Chronic kidney disease

Ozempic receives FDA nod for treating chronic kidney disease

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

CNBC on MSN · 2d

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

People on MSN · 1d

FDA Approves Ozempic to Treat Kidney Disease

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease.

FDA approves Ozempic for diabetes patients to cut kidney disease risk

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...

MM&M18h

Rx Rundown: Merck, Biogen, Pfizer and more

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Seeking Alpha5h

2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment

Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable ...

19h

Q&A: How a scientist helped ban a chemical connected to Parkinson's disease

The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...

Renal & Urology News1d

KDIGO Issues New ADPKD Guideline

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results